Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S against adult and pediatric human tumor colony-forming units

Anti-Cancer Drugs

Volumn 10, Issue 9, 1999, Pages 837-844

  Hidalgo, Manuel ^b   Izbicka, Elzbieta ^b,c   Eckhardt, S Gail ^b   Macdonald, John R ^a,b   Cerna, Cesario ^b   Gomez, Lionel ^b   Rowinsky, Eric K ^b   Weitman, Steven D ^b   Von Hoff, Daniel D ^b  

^a GUILFORD PHARMACEUTICALS INC   (United States)

^b CTRC Institute for Drug Development   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

6 Hydroxymethylacylfulvene; Adult; Human tumor cloning assay; MGI 114; Pediatric

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG RESISTANCE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME; TISSUE CULTURE;

EID: 0033429321     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199910000-00007     Document Type: Article

References (21)

1. 1. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma model nonresponsive to traditional anticancer agents. Invest New Drugs 1996; 141: 161-7.
2. 2. McMorris TC, Kelner MJ, Wang W, et al. Hydroxymethylacylfulvene (HMAF), an illudin derivative with superior antitumor properties. J Nat Prod 1996; 59: 896-99.
3. 3. Kelner MJ, McMorris TC, Beck WT, et al. Preclinical evaluation of illudins as anticancer agents. Cancer Res 1987; 47: 3186-89.
4. 4. Kelner MJ, McMorris TC, Taetle R. Preclinical evaluation of illudins as anticancer agents: basis for selective toxicity. J Natl Cancer Inst 1990; 82: 1562-5.
5. 5. Kelner MJ, McMorris TC, Estes L, et al. Characterization of illudin S sensitivity in DNA repair deficient Chinese Hamster cells: unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 1994; 48. 403-9.
6. 6. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 helicase-deficient cells. Cancer Res 1995; 55: 4936-40.
7. 7. Kelner MJ, McMorris TC, Taetle R. In vitro and in vivo studies on the anticancer activity of dehydroillidin M. Anticancer Res 1995; 15: 873-8.
8. 8. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997; 57: 279-83.
9. 9. Mangold G, MacDonald. J, Von Hoff DD, et al. Antitumor activity of MGI 114 against two human prostate tumor xenograft models. Ann Oncol 1998; 9: 37 (abstr 142).
10. 10. Mangold G, MacDonald J, Von Hoff DD, et al. Enhance antitumor activity of MGI 114 in combination with paclitaxel and topotecan against a human lung tumor xenograft model. Ann Oncol 1998; 9: 37 (abstr 141).
11. 11. Marty J, MacDonald J, Mangold G, et al. Evidence of synergistic antitumor activity with MGI 114 in combination with irinotecan (ITN) or 5-fluorouracil (5-FU) against a human colon tumor xenograft model. Proc Am Ass Clin Oncol 1998; 39: 527.
12. 12. Eckhardt SG, Baker SD, Moczygemba J, et al. A phase I and pharmacokinctic (PK) study of the novel mushroom-derived cytotoxin, MGI-114, in patients with advanced cancer. Ann Oncol 1998; 9: 123 (abstr 471).
13. 13. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. J Clin Invest 1977; 60: 846-54.
14. 14. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 471.
15. 15. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an In vitro assay versus a clinician. J Natl Cancer Inst 1990; 82: 110-6.
16. 16. Shoemaker RH, Wolpert-Defillpes MK, Kern DH, et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2145-53.
17. 17. Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted tumor cells. Anti-Cancer Drugs 1992; 3: 121-4.
18. 18. Raymond E, Izbicka E, Soda H, et al. Activity of temozolomide against human colony-forming units. Clin Cancer Res 1997; 3: 1769-74.
19. 19. Ali-Osman F, Giblin J, Dougherty D, et al. Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in human tumor clonogenic cell assay. Cancer Res 1987; 47: 3718-24.
20. 20. Friedman HS, Schold SC, Muhlbaier LH, et al. In vitro versus in vivo correlations of chemosensitivity of human meduloblastoma. Cancer Res 1984; 44: 5145-9.
21. 21. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr/gp170 metastatic MV522 lung carcinoma xenograft. 1998; 34: 908-13.